Safety Outcomes
The frequency of adverse events related to the statin therapy was very low in both groups, with myopathy occurring in around 0.8% and increased ALT > three ULN in around 0.7% in both groups as presented in Table 4 . Only three patients (0.3%) in the atorvastatin 40mg group and no patient in the 80mg group discontinued the statin therapy secondary to adverse events.